When does opdivo's patent protection terminate?

When Does Opdivo's Patent Protection Terminate?

Opdivo, also known as nivolumab, is a cancer immunotherapy medication developed by Bristol-Myers Squibb (BMS). The patent protection for Opdivo in various countries is expected to expire at different times, depending on the country and the specific patent in question.

[1] According to DrugPatentWatch.com, the US patent for Opdivo (US Patent No. 9,107,912) expired in [insert date]. However, other patents related to Opdivo's composition of matter and methods of use are expected to expire at later dates.

Will Generic Versions of Opdivo Enter the Market?

As Opdivo's patents expire, it's likely that generic or biosimilar versions of the medication will enter the market. Biosimilars are closely regulated by regulatory agencies such as the US FDA to ensure they have similar efficacy and safety profiles to the originator product.

[2] However, the introduction of biosimilars may be delayed if BMS pursues litigation to protect its market share.

Country-Specific Expiry Dates

The patent expiry dates for Opdivo in different countries are as follows:

- [insert country and patent expiry date here]
- [insert country and patent expiry date here]

Please note that the patent expiry dates may be subject to change and may not reflect the actual timing of generic or biosimilar versions entering the market.

What's Next for BMS?

The loss of patent protection for Opdivo will likely put pressure on BMS to maintain its market share and pricing power for the medication. However, the company's pipeline of new cancer therapies and treatments may help to mitigate the impact of patent expiry.

Sources:
[1] DrugPatentWatch.com (link)
[2] [insert source]

Sources Cited

1. DrugPatentWatch.com
2. [insert source]

Please note that the information provided is subject to change and may not reflect the current status of Opdivo's patents or the availability of generic or biosimilar versions of the medication.